Owning ASX shares that deliver long-term capital growth is exciting. Some winners continue winning, and that's what I'm expecting with the three investments I'm going to highlight in this article.
The best ASX investment I ever made was Altium, an electronic PCB software business benefiting from strong demand amid the world's increasingly technological nature. Sadly, Altium was acquired and taken off the ASX.
I'm going to run through three of my current biggest winners and outline which one I'm planning to buy in 2027. This list may have looked a little different at the start of 2025, but many ASX growth shares have sold off since then, so my biggest winners list has changed.
The first business I'll highlight is the healthcare technology company Pro Medicus, which is making impressive progress in the US as it wins new contracts and renews existing ones at higher transaction rates.
Thankfully, I've been a shareholder for a few years and have ridden the significant growth in earnings and the Pro Medicus share price.
For me, it may be the best business on the ASX, with an EBIT (operating profit) margin of around 75% and regular annual growth of more than 20%.
It's true that it has a high price-to-earnings (P/E) ratio, which is why I'm glad I made investments when the business had a lower P/E ratio. While the earnings multiple may seem high today, investors can just be patient and watch the business report excellent growth year after year.
In FY26, underlying net profit increased 24.1% to $144.7 million, and on a constant currency basis, its net profit rose 32.5% to $154.5 million.
Considering it signed 10 contracts in FY26 worth at least A$407 million, I think the prospect of growth in FY27 looks very positive as those contracts start coming online. Its pipeline remains strong, and its market share is only 11% in the US market, suggesting there's still plenty of room to grow.
Considering I'm already a shareholder, I'm looking for a better P/E ratio before investing even more.
I like to invest in listed investment companies (LICs) because of the combination of dividends and capital growth they can provide.
I started investing in this LIC a number of years ago when its share price was a lot lower, and it was trading at a sizeable discount to its net tangible assets (NTA). Since then, the portfolio return has been exceptional.
One of the most famous pieces of advice from Warren Buffett – one of the world's greatest ever investors – was "be fearful when others are greedy and greedy when others are fearful."
The investment team do typically like to look at unloved businesses or sectors where there's good potential for earnings per share (EPS) growth, yet the P/E ratio is trading at an attractively low earnings multiple.
Staying away from crowded trades (and potentially shorting overhyped names) has helped the LIC deliver good returns. Over the last seven years, the L1 Long Short Fund portfolio's net return has been an average of 19.4% per year. A lot of that return has helped drive the share price (and also pay for a growing dividend).
However, I'll be focusing my L1 LIC investing on L1 Global Long Short Fund Ltd (ASX: GLS) because of the increased focus on international shares compared to L1 Long Short Fund (LSF). LSF is already a significant part of my portfolio, so I'm happy leaving it at that weighting.
In terms of capital gains in dollar terms, Soul Patts has made the most for my portfolio, partly because of how much I've invested in the business.
Soul Patts was one of my first positions more than a decade ago, and I have steadily built my long-term holding.
While it has paid a growing dividend each year for almost three decades, it has been the growing portfolio value that has helped drive the value of Soul Patts shares. The investment house takes long-term stakes in businesses and other assets that can grow themselves over time.
I also like that Soul Patts retains a minority of its net cash flow each year; it can invest that money into new opportunities.
With a focus on defensive businesses that generate good cash flow, I believe Soul Patts can continue to deliver in all economic conditions.
The fact that it has the flexibility to invest in all sectors makes me believe the business can continue to future-proof itself as it regularly makes new investments (and sells others).
I expect I'll own Soul Patts over the coming decades and benefit from rising dividends.
The post My 3 biggest ASX portfolio winners and the one I'm buying more of appeared first on The Motley Fool Australia.
Motley Fool contributor Tristan Harrison has positions in L1 Global Long Short Fund Ltd, L1 Long Short Fund, Pro Medicus, and Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended Pro Medicus. The Motley Fool Australia has positions in and has recommended Washington H. Soul Pattinson and Company Limited. The Motley Fool Australia has recommended Pro Medicus. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2026